AbbVie, Neomorph to develop molecular glue degraders

AbbVie (NYSE:ABBV) has entered into a collaboration agreement with Neomorph for the development of novel molecular glue degraders for multiple targets across oncology and immunology.

Under the deal, Neomorph will receive an upfront payment and is eligible to receive up to $1.64B